Teva Pharmaceutical Industries (TEVA) return on equity (ROE)

Return on equity · fiscal 2025
17.8%

Teva Pharmaceutical Industries (TEVA) earned a return on equity of 17.8% in fiscal 2025 (the year ended December 31, 2025). That is 48.3 percentage points higher than the -30.5% of fiscal 2024. Figures as of 18 Nov 2026, 01:42 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
17.8%
Change on fiscal 2024
+48.3 pts
Highest on record
17.8%fiscal 2025
Lowest on record
-93.7%fiscal 2017
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Teva Pharmaceutical Industries return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 17.8% in fiscal 2025 and the lowest -93.7% in fiscal 2017. The fiscal 2025 figure is higher than in every one of the 18 earlier fiscal years on record, whose median is 3.9%.

History · 19 fiscal years

Return on equity by fiscal year

Teva Pharmaceutical Industries return on equity (ROE), year by year

Teva Pharmaceutical Industries (TEVA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202517.8% 48.3 pts up
2024-30.5% 23.1 pts down
2023-7.4% 23.9 pts up
2022-31.3% 35.4 pts down
20214.1% 43.9 pts up
2020-39.8% 32.6 pts down
2019-7.2% 7.5 pts up
2018-14.6% 79.1 pts up
2017-93.7% 94.7 pts down
20161.0% 4.3 pts down
20155.3% 7.8 pts down
201413.1% 7.5 pts up
20135.6% 3.0 pts down
20128.6% 3.8 pts down
201112.4% 2.7 pts down
201015.2% 4.8 pts up
200910.4% 6.7 pts up
20083.7% 10.1 pts down
200713.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Teva Pharmaceutical Industries and comparable companies
CompanyReturn on equityFiscal year
Medline MDLN10.8%2025
Humana HUM6.7%2025
Agilent Technologies A19.3%2025
Teva Pharmaceutical Industries TEVA17.8%2025
BeOne Medicines ONC6.6%2025
Waters WAT25.1%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TEVA

Teva Pharmaceutical Industries, figure by figure

Teva Pharmaceutical Industries (TEVA) overview: price, valuation and scorecardAll health care companies by market value

Teva Pharmaceutical Industries return on equity (ROE): questions and answers

What is Teva Pharmaceutical Industries's return on equity?

Teva Pharmaceutical Industries (TEVA) earned a return on equity of 17.8% in fiscal 2025 (the year ended December 31, 2025). That is 48.3 percentage points higher than the -30.5% of fiscal 2024.

Is Teva Pharmaceutical Industries's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 18 earlier fiscal years on record, whose median is 3.9%.

What are the highest and lowest return on equity figures on record for Teva Pharmaceutical Industries?

Across the 19 fiscal years on record (2007–2025), the highest was 17.8% in fiscal 2025 and the lowest -93.7% in fiscal 2017.

How is Teva Pharmaceutical Industries's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Teva Pharmaceutical Industries (TEVA) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/TEVA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.